Article
The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.
Oncotarget - 24 Nov 2015
Mazzacurati Lucia, Lambert Que T, Pradhan Anuradha, Griner Lori N, Huszar Dennis, Reuther Gary W
Abstract excerpt
Classical myeloproliferative neoplasms (MPNs) are hematopoietic stem cell disorders that exhibit excess mature myeloid cells, bone marrow fibrosis, and risk of leukemic transformation. Aberrant JAK2 signaling plays an etiological role in MPN formation. Because neoplastic cells in patients are largely insensitive to current anti-JAK2 therapies, effective therapies remain needed. Members of the PIM family of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.